NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse

Acute myeloid leukemia (AML) with NPM1 mutation (NPM1(mut)) defines a World Health Organization entity. Absence of minimal residual disease (MRD) following induction chemotherapy is associated with an excellent prognosis. Data are conflicting on NPM1(mut) AML relapsing with wild-type NPM1 (NPM1(wt))...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Höllein, Alexander, Meggendorfer, Manja, Dicker, Frank, Jeromin, Sabine, Nadarajah, Niroshan, Kern, Wolfgang, Haferlach, Claudia, Haferlach, Torsten
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Myeloid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258925/
https://ncbi.nlm.nih.gov/pubmed/30455361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018023432
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia